# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and maintains $7...
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Neutral and maintains $5 p...
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small c...
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Neutral and maintains $5 p...
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Neutral and maintains $5 p...
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate o...
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor ...
-SEC Filing